Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL)

Shah, B., Challagulla, S., Xu, S. et al. (5 more authors) (2024) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). In: Clinical Lymphoma Myeloma and Leukemia. Society of Hematologic Oncology 2024 Annual Meeting, 04-07 Sep 2024, Houston, Texas, USA. Elsevier BV. Article no: MCL-509, S227-S227. ISSN: 2152-2650.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2024 Elsevier Inc
Keywords: Biomedical and Clinical Sciences; Cardiovascular Medicine and Haematology; Oncology and Carcinogenesis; Clinical Trials and Supportive Activities; Lymphoma; Rare Diseases; Orphan Drug; Hematology; Clinical Research; Cancer; Lymphatic Research
Dates:
  • Published (online): September 2024
  • Published: September 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Date Deposited: 20 Jan 2026 10:33
Last Modified: 20 Jan 2026 10:34
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: 10.1016/s2152-2650(24)00895-4
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)